Skip to main content
Skip to main content
HCAT logo

Health Catalyst, Inc. (HCAT) Stock Analysis

$1.63 -$0.06 (-3.55%) |Avoid · 17
Health Catalyst, Inc. (HCAT) bottom line: signals are mixed — the Council read leans Split View (35/100) while the AI fundamental score is 17/100 (grade F); the two lenses disagree, so weigh the breakdown below. Strongest signal: Ken Griffin bullish · Biggest watch-out: Izzy Englander bearish.
MCap: $120M| Vol: 523.2K| Target: $2.50 (+53.4%)| 52-wk range: $0.955 – $4.12
Data from FMP · Methodology

For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Health Catalyst, Inc. (HCAT) trades at $1.63 with AI Score 17/100 (Grade F). Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. Market cap: $120M, Sector: Healthcare.

Price as of Aug 20, 2026 · Last analyzed: May 10, 2026
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. The company's offerings include a data and analytics platform, AI and data science integration, and population health management solutions.

HCAT stock analysis for 2026: Analysts have set a consensus price target of $2.50 for Health Catalyst, Inc., suggesting 53.4% upside from the current price of $1.63. The AI MoonshotScore is 17/100, indicating a strong bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.

Watch the HCAT film Every key number, told as a short cinematic story — just press play. ~2 min
Council Score · Weighted Average of 3 Disciplines
Split View 35/100 · D

HCAT: 2/3 scored disciplines lean bearish. Dominant signal: Ken Griffin bullish.

How is this calculated? →
MoonshotScore · Growth Potential · 17/100
Business Quality
Weak Is this a genuinely good business?
Financial Safety
Weak Could this blow up on me?
Valuation
Neutral Am I paying a fair price?
Growth Durability
Weak Is the growth real and likely to last?
Momentum
Weak Is the market already moving on this?
Legends Council · 5 Legends + Moon AI
Ray Dalio
Bullish
Ken Griffin
Bullish
Jim Simons
Neutral
Izzy Englander
Bearish
Seth Klarman
Bullish
Moon AI
Neutral
Munger's Mindset · Balance Sheet & Valuation
Financial Health
Negative
Margin of Safety
Undervalued
Council Score · Weighted Average of 3 Disciplines · See tabs for details →

Why this analysis is different

  • A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
  • An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
  • Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Health Catalyst, Inc. (HCAT) Healthcare & Pipeline Overview

CEODaniel D. Burton
Employees1,500
HeadquartersSouth Jordan, UT, US
IPO Year2019

Health Catalyst, Inc. delivers data and analytics solutions to healthcare organizations, focusing on improving clinical, financial, and operational outcomes. Its platform integrates AI and data science to enhance business intelligence, offering services from population health management to financial transformation within the evolving healthcare landscape.

Data Provenance | Financial Data Quantitative Analysis NASDAQ Analysis: May 10, 2026

What Is the Investment Thesis for HCAT?

As of May 10, 2026 — figures reflect the data available on that date.

Health Catalyst operates in the growing healthcare analytics market, driven by the increasing demand for data-driven insights to improve patient outcomes and reduce costs. The company's comprehensive suite of data and analytics solutions positions it to capitalize on this trend. However, with a current market capitalization of $120M and a negative profit margin of -57.2%, the company faces significant challenges in achieving profitability. A key value driver is the company's ability to expand its customer base and increase adoption of its platform and services. Upcoming catalysts include potential partnerships with larger healthcare organizations and the launch of new AI-powered analytics solutions. Investors should monitor the company's progress in improving its financial performance and achieving sustainable growth.

Based on FMP financials and quantitative analysis

HCAT Key Highlights

Market capitalization of $120M, reflecting its current valuation in the market.

  • Negative profit margin of -57.2%, indicating challenges in achieving profitability.
  • Gross margin of 33.5%, showcasing the profitability of its core services before operating expenses.
  • Beta of 1.81, suggesting higher volatility compared to the overall market.
  • No dividend yield, as the company does not currently distribute dividends to shareholders.

Who Are HCAT's Competitors?

HCAT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap AI Score
ORCL Oracle Corporation $142.05 -1.22% $409B 50
ONVVF Oneview Healthcare PLC $0.16 +0.00% $123M 60
AUGX Augmedix, Inc. $2.35 -0.21% $116M 58
CCLD CareCloud, Inc. $2.64 +1.93% $112M 69
OPRX OptimizeRx Corporation $8.08 +0.87% $152M 87
VPAHF Volpara Health Technologies Limited $0.74 +36.63% $188M 60
SPOK Spok Holdings, Inc. $10.48 -0.03% $219M 83
SMFR Sema4 Holdings Corp. $0.31 +26.78% $246M 60

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are HCAT's Key Strengths?

Comprehensive data and analytics platform.

  • Expertise in AI and data science.
  • Focus on the healthcare sector.
  • National data ecosystem.

What Are HCAT's Weaknesses?

Negative profit margin.

  • Relatively small market capitalization.
  • High beta indicating volatility.
  • Dependence on healthcare organizations' willingness to adopt new technologies.

What Could Drive HCAT Stock Higher?

Potential partnerships with larger healthcare organizations to expand market reach.

  • Launch of new AI-powered analytics solutions to enhance platform capabilities.
  • Increasing adoption of value-based care driving demand for population health management solutions.
  • Growing need for data-driven insights to improve patient outcomes and reduce costs.

What Are the Key Risks for HCAT?

Financial-distress signal — its Altman Z-Score of -6.57 sits in the distress zone (elevated bankruptcy risk).

  • Negative return on equity (-99.8%) — the business is not currently generating profit on shareholder capital.
  • Intense competition from larger companies with greater resources.
  • Regulatory changes in the healthcare industry affecting data privacy and security.
  • Negative profit margin and challenges in achieving profitability.
  • Dependence on healthcare organizations' willingness to adopt new technologies.

What Are the Growth Opportunities for HCAT?

  • Expansion of AI and Data Science Offerings: Health Catalyst can leverage its AI and data science capabilities to develop new solutions that address specific healthcare challenges, such as predicting patient readmissions or identifying high-risk patients. The market for AI in healthcare is projected to reach $34 billion by 2027, offering a substantial growth opportunity for Health Catalyst. By integrating AI into its existing platform, the company can enhance its value proposition and attract new customers.
  • Strategic Partnerships with Healthcare Providers: Forming strategic partnerships with large healthcare providers can provide Health Catalyst with access to a broader customer base and valuable data. These partnerships can also enable the company to co-develop new solutions and tailor its offerings to meet the specific needs of its partners. The timeline for these partnerships can vary, but successful collaborations can drive significant revenue growth and market share gains.
  • Geographic Expansion: Health Catalyst can expand its geographic reach by targeting new markets outside of the United States. The global healthcare analytics market is expected to grow significantly in the coming years, presenting opportunities for Health Catalyst to establish a presence in new regions. This expansion can be achieved through direct sales, partnerships with local distributors, or acquisitions of complementary businesses.
  • Focus on Population Health Management: With the increasing emphasis on value-based care, Health Catalyst can capitalize on the growing demand for population health management solutions. By providing tools and services that help healthcare organizations identify and manage high-risk populations, the company can improve patient outcomes and reduce healthcare costs. The market for population health management is projected to reach $69.2 billion by 2030, offering a significant growth opportunity for Health Catalyst.
  • Development of a National Data Ecosystem: Health Catalyst's national data ecosystem can serve as a valuable asset for thought leadership and knowledge exchange. By fostering collaboration among healthcare organizations and providing access to a vast amount of data, the company can drive innovation and improve care delivery across the industry. This ecosystem can also attract new customers and partners, further strengthening Health Catalyst's market position.

What Are HCAT's Competitive Advantages?

  • Proprietary data and analytics platform tailored for healthcare.
  • Expertise in AI and data science applied to healthcare challenges.
  • Established relationships with healthcare organizations.
  • National data ecosystem fostering knowledge exchange.

What Does HCAT Do?

Founded in 2008 and headquartered in South Jordan, Utah, Health Catalyst, Inc. emerged from a vision to transform healthcare through data and analytics. Initially known as HQC Holdings, Inc., the company rebranded as Health Catalyst, Inc. in March 2017, marking a pivotal shift towards its current focus. Health Catalyst provides a suite of technology and services designed to help healthcare organizations improve their performance. Its core offering is a data and analytics platform tailored for the healthcare sector, providing a commercial-grade infrastructure for managing and analyzing vast amounts of clinical, financial, and operational data. This platform enables healthcare providers to gain actionable insights, improve patient outcomes, and reduce costs. In addition to its platform, Health Catalyst offers AI and data science solutions, integrating artificial intelligence into existing business intelligence tools to enhance analytics accuracy and predictive capabilities. The company's services also include population health management, which identifies opportunities for improvement across the care continuum, offering guidance and automated workflows to drive success. Furthermore, Health Catalyst provides financial transformation solutions, delivering insights into costing, labor productivity, and revenue capture. The company also focuses on quality and safety improvement, leveraging clinical quality and patient safety data, analytics, and expert services to enhance healthcare delivery. Health Catalyst's national data ecosystem fosters thought leadership and knowledge exchange, aiming to transform care delivery through next-generation insights. With approximately 1,500 employees, Health Catalyst serves a diverse range of healthcare organizations, including hospitals, health systems, and accountable care organizations.

What Products and Services Does HCAT Offer?

  • Provides a data and analytics platform for healthcare organizations.
  • Offers AI and data science solutions to enhance business intelligence.
  • Delivers population health management tools and services.
  • Provides financial transformation solutions for costing and labor productivity insights.
  • Offers quality and safety improvement services using clinical data.
  • Maintains a national data ecosystem for knowledge exchange.

How Does HCAT Make Money?

  • Provides subscription-based access to its data and analytics platform.
  • Offers professional services for implementation, training, and support.
  • Generates revenue from AI and data science solutions.
  • Provides population health management and financial transformation services.

What Industry Does HCAT Operate In?

Health Catalyst operates within the healthcare information services industry, which is experiencing significant growth due to the increasing adoption of electronic health records (EHRs) and the growing need for data-driven insights to improve healthcare delivery. The market is competitive, with companies like Cerner (ORCL) and Allscripts (Unknown) offering similar solutions. Health Catalyst differentiates itself through its focus on providing a comprehensive data and analytics platform specifically designed for the healthcare sector. The industry is expected to continue to grow as healthcare organizations increasingly invest in data analytics to improve patient outcomes, reduce costs, and comply with regulatory requirements.

Who Are HCAT's Key Customers?

  • Hospitals
  • Health systems
  • Accountable care organizations (ACOs)
AI Confidence: 66% Updated: May 10, 2026

Company Profile

Health Catalyst, Inc. operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in South Jordan, US. The company is led by CEO Benjamin Albert. HCAT has traded publicly since 2019.

Health Catalyst, Inc. Financial Trajectory

Health Catalyst, Inc. (HCAT) reported $70.5M in revenue for Q2 2026, a decline of 0.4% compared to the prior quarter. The company recorded a net loss of $40.5M, with diluted EPS of $-0.55. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely. Across the four most recent quarters, HCAT averaged $-0.92 in diluted EPS.

How Health Catalyst, Inc. Is Valued

Health Catalyst, Inc. carries a market capitalization of $120M, placing it in the micro-cap category. Relative to its peer group, HCAT's quantitative score of 17/100 is below the peer average of 65/100.

ROE -100%

Key Financial Metrics

Return on equity for Health Catalyst, Inc. stands at -99.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -64.4%, showing how much profit it generates from its asset base. Its free cash flow yield is 6.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.69 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -176.5%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 5/9

Financial Health

Health Catalyst, Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -6.57 places it in the distress zone, a signal of elevated financial risk.

4/8 beats

Earnings Track Record

Health Catalyst, Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 10.3% above estimates on average.

FY2026 est

Forward Outlook

Wall Street analysts project Health Catalyst, Inc. revenue of about $263.8M for fiscal 2026, with EPS near $0.06. The estimate reflects 3 contributing analysts.

HCAT Financials

Fundamental Snapshot

Revenue Growth (FY)
+1.5%
Net Income Growth (FY)
-156.1%
EPS Growth (FY)
-121.7%
Free Cash Flow Growth (FY)
+87.1%
Return on Equity (TTM)
-99.8%
Current Ratio
1.7

Based on FMP financials and quantitative analysis · FY 2025

Bull Case vs Bear Case

Bull Case

  • Comprehensive data and analytics platform.
  • Expertise in AI and data science.
  • Focus on the healthcare sector.
  • National data ecosystem.

Bear Case

  • Negative profit margin.
  • Relatively small market capitalization.
  • High beta indicating volatility.
  • Dependence on healthcare organizations' willingness to adopt new technologies.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026

Recent Quarterly Results

Quarter Revenue Net Income EPS
Q2 2026 $70M -$41M -$0.55
Q1 2026 $71M -$111M -$1.53
Q4 2025 $75M -$91M -$1.28
Q3 2025 $76M -$22M -$0.32

Based on FMP financials and quantitative analysis

HCAT Latest News

HCAT Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HCAT.

Price Targets

Consensus target: $2.50

HCAT MoonshotScore

17/100

What does this score mean?

The MoonshotScore rates HCAT 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.

Leadership: Benjamin Albert

CEO

Benjamin Albert serves as the CEO of Health Catalyst, leading a team of 1,500 employees. His background includes extensive experience in healthcare technology and data analytics. He has held various leadership positions in the industry, focusing on driving innovation and improving patient outcomes through data-driven solutions. Albert's expertise spans across strategic planning, product development, and market expansion.

Track Record: Under Benjamin Albert's leadership, Health Catalyst has focused on expanding its AI and data science capabilities, aiming to enhance the accuracy and predictive power of its analytics platform. He has overseen the development of new solutions for population health management and financial transformation, driving growth in key areas. His strategic decisions have focused on strengthening the company's market position and improving its financial performance.

Common Questions About HCAT (Healthcare)

What does the AI Score mean for HCAT?

HCAT holds an AI Score of 17/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. The company's offerings include a data and analytics platform, AI and data science …

What does Health Catalyst, Inc. do?

Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. Its core offering is a commercial-grade data and analytics platform designed specifically for the healthcare sector. This platform enables healthcare providers to manage and analyze vast amounts of clinical, financial, and operational data, providing actionable insights to improve patient outcomes and reduce costs.

What do analysts say about HCAT stock?

Analyst coverage of Health Catalyst, Inc. is limited, reflecting its small market capitalization and negative profitability. However, analysts generally recognize the company's potential in the growing healthcare analytics market. Key valuation metrics, such as price-to-sales ratio, are used to assess the company's value relative to its peers.

What are the main risks for HCAT?

Health Catalyst faces several key risks, including intense competition from larger companies with greater resources, regulatory changes in the healthcare industry affecting data privacy and security, and its current negative profit margin. The company's dependence on healthcare organizations' willingness to adopt new technologies also poses a risk.

What are the key factors to evaluate for HCAT?

Health Catalyst, Inc. (HCAT) holds an AI score of 17/100 (low). Analysts target $2.50 (+53%). Health Catalyst operates in the growing healthcare analytics market, driven by the increasing demand for data-driven insights to improve patient outcomes and reduce costs. Not financial advice.

How frequently does HCAT data refresh on this page?

HCAT's price was last updated on Aug 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.

What has driven HCAT's recent stock price performance?

Health Catalyst, Inc. (HCAT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Comprehensive data and analytics platform. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider HCAT overvalued or undervalued right now?

Health Catalyst, Inc. (HCAT) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Analysts target $2.50 (+53%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research HCAT before investing?

Before investing in Health Catalyst, Inc. (HCAT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated AI Score refreshed daily
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Financial data is based on the most recent available information.
  • Market projections are based on industry reports and analyst estimates.
  • Competitive landscape is subject to change.
Data Sources

Popular Stocks

More Stocks We Cover